Drug intelligence / Profile preview

Saburgen

Development stage: Unknown
Lead developer: Weber & Weber
Administration: Oral

Overview

Saburgen is a German nonprescription homeopathic oral liquid mixture marketed by Weber & Weber as adjunctive therapy for prostate disorders, including symptomatic complaints associated with benign prostatic enlargement. It contains homeopathic preparations of *Clematis recta*, *Lytta vesicatoria*, *Chondrodendron*, *Populus tremuloides*, and *Serenoa repens*. The official labeling states that it may improve symptoms associated with an enlarged prostate but does not reduce the enlargement itself; its therapeutic indication is derived from homeopathic medicinal pictures rather than a defined molecular pharmacologic mechanism. ([weber-weber.de](https://weber-weber.de/produkte/saburgen/))

Brand names: Saburgen
Other names: Saburgen MischungSaburgen Tropfen

Beyond the preview

Go deeper on Saburgen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saburgen.

Explore the full profile